Humanigen, Inc. (HGEN) is a **clinical-stage biopharmaceutical** company founded in **2001**, with a focus on transforming the treatment of cancers and infectious diseases, including COVID-19. The company is dedicated to preventing and treating cytokine storm through its innovative anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, hold promise in the prevention and treatment of conditions induced by cytokine storm, such as SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy, and graft versus host disease (GvHD) by neutralizing GM-CSF, which is up-regulated in these conditions. In March 2021, the company secured a significant **$92.50M Post-IPO Equity** investment. This demonstrates investor confidence in the potential of Humanigen's innovative approach to addressing critical medical needs.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $92.50M | - | 31 Mar 2021 | |
| Post-IPO Debt | $80.00M | 1 |
|
10 Mar 2021 |
| Post-IPO Equity | $72.80M | - | 17 Sep 2020 | |
| Post-IPO Debt | $5.00M | - | 12 Jul 2017 | |
| Post-IPO Equity | $11.00M | 3 |
|
01 Jul 2016 |
No recent news or press coverage available for Humanigen, Inc..
We care about your data, and we'd love to use cookies make your experience better.
